Industry: Pharmaceuticals, Biotechnology
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev’s product candidates are based on C1-esterase inhibitor (“C1-INH”), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The Company initiated a Phase III clinical trial of its lead product candidate, C1-INH for the treatment of hereditary angioedema, in March 2005. Lev is also developing C1-INH for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role. ( www.levpharma.com )
Lev Pharmaceuticals , Inc.
122 East 42Nd Street Suite 2606
New York, New York 10168
USA
Tel: (212) 682-3096
Fax: (212) 682-3994